Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Stoke Therapeutics is a late-stage biotech company developing RNA-based medicines using its proprietary TANGO platform to upregulate protein expression. Focused on severe genetic diseases like Dravet syndrome and ADOA, it designs antisense oligonucleotides to restore normal protein levels, addressing underlying causes. The company collaborates globally for development and commercialization, aiming to deliver disease-modifying therapies for central nervous system and eye disorders.
This description was generated via AI from an annual report. Updated about 1 year ago.